MX2022015858A - Antagonistas del receptor del factor liberador de corticotropina. - Google Patents

Antagonistas del receptor del factor liberador de corticotropina.

Info

Publication number
MX2022015858A
MX2022015858A MX2022015858A MX2022015858A MX2022015858A MX 2022015858 A MX2022015858 A MX 2022015858A MX 2022015858 A MX2022015858 A MX 2022015858A MX 2022015858 A MX2022015858 A MX 2022015858A MX 2022015858 A MX2022015858 A MX 2022015858A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
factor receptor
releasing factor
corticotropin releasing
dimethylpyrazolo
Prior art date
Application number
MX2022015858A
Other languages
English (en)
Inventor
Alexis Howerton
Hal Gerber
Sami Karaborni
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Publication of MX2022015858A publication Critical patent/MX2022015858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona nuevas composiciones farmacéuticas que comprenden la 3-(4-cloro-2-(morfolin-4-il)tiazol -5-il)-7-(1-etilpropil)-2,5-dimetilpirazolo(1,5-a)pirimidina y métodos para el uso de la misma para el tratamiento de la hiperplasia suprarrenal congénita (CAH).
MX2022015858A 2017-08-14 2019-12-16 Antagonistas del receptor del factor liberador de corticotropina. MX2022015858A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762545393P 2017-08-14 2017-08-14

Publications (1)

Publication Number Publication Date
MX2022015858A true MX2022015858A (es) 2023-01-24

Family

ID=65362465

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015318A MX2019015318A (es) 2017-08-14 2018-08-14 Antagonistas del receptor del factor liberador de corticotropina.
MX2022015858A MX2022015858A (es) 2017-08-14 2019-12-16 Antagonistas del receptor del factor liberador de corticotropina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019015318A MX2019015318A (es) 2017-08-14 2018-08-14 Antagonistas del receptor del factor liberador de corticotropina.

Country Status (13)

Country Link
US (1) US20210137935A1 (es)
EP (1) EP3630763A4 (es)
JP (2) JP7285222B2 (es)
KR (1) KR102644781B1 (es)
CN (1) CN110997667A (es)
AR (1) AR112471A1 (es)
AU (2) AU2018318990B2 (es)
BR (1) BR112020002966A2 (es)
CA (1) CA3064445A1 (es)
EA (1) EA202090321A1 (es)
MX (2) MX2019015318A (es)
TW (2) TW202400179A (es)
WO (1) WO2019036472A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015209452C1 (en) 2014-01-21 2020-11-05 Neurocrine Biosciences, Inc. CRF1 receptor antagonists for the treatment of congenital adrenal hyperplasia
BR112020024062A2 (pt) 2018-04-27 2021-02-09 Spruce Biosciences, Inc. métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
AU2020318970A1 (en) * 2019-07-19 2022-03-03 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
BR112023002497A2 (pt) * 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123835A0 (en) * 1996-02-07 1998-10-30 Janssen Pharmaceutica Nv Pyrazolopyrimidines as CRF receptor antagonists
IL137019A (en) * 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
CN1137123C (zh) 1998-01-28 2004-02-04 杜邦药品公司 吡咯并三嗪和嘧啶化合物
WO2001041761A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Valdecoxib compositions
US20070129382A1 (en) * 2004-02-13 2007-06-07 Dimitri Grigoriadis Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses
BRPI0608857A2 (pt) 2005-03-21 2012-08-28 Lilly Co Eli composto, e, composição farmacêutica
UA96458C2 (ru) * 2006-09-20 2011-11-10 Эли Лилли Энд Компани Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
ES2428543T3 (es) * 2006-09-20 2013-11-08 Eli Lilly And Company Compuestos de tiofenopirazolopirimidina
US8563718B2 (en) * 2008-10-02 2013-10-22 Eli Lilly And Company Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes

Also Published As

Publication number Publication date
KR102644781B1 (ko) 2024-03-06
JP2020530832A (ja) 2020-10-29
JP7285222B2 (ja) 2023-06-01
US20210137935A1 (en) 2021-05-13
WO2019036472A1 (en) 2019-02-21
KR20200038951A (ko) 2020-04-14
AR112471A1 (es) 2019-10-30
AU2023201703A1 (en) 2023-04-13
CA3064445A1 (en) 2019-02-21
CN110997667A (zh) 2020-04-10
AU2018318990A1 (en) 2019-11-21
TW201925197A (zh) 2019-07-01
EP3630763A4 (en) 2021-03-10
TWI803504B (zh) 2023-06-01
EA202090321A1 (ru) 2020-09-24
JP2023116489A (ja) 2023-08-22
AU2018318990B2 (en) 2023-01-05
TW202400179A (zh) 2024-01-01
MX2019015318A (es) 2020-07-20
BR112020002966A2 (pt) 2020-08-11
EP3630763A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
MX2022015858A (es) Antagonistas del receptor del factor liberador de corticotropina.
MX2023000501A (es) Antagonistas del receptor del factor liberador de corticotropina.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
DOP2017000199A (es) Receptores de antígeno quiméricos ant- dll3 y métodos de uso
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
SI3230298T1 (sl) Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MX2022004937A (es) Inhibidores de las cinasas raf.
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
SA518400333B1 (ar) شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
PH12017500161A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PH12017500170A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
WO2019123294A3 (en) Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus
JO3601B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
SI3596080T1 (sl) Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati
MX2021004918A (es) Derivados de benzodiazepina heterociclica fusionada y usos de estos.